Navigenics Nets $18M in Financing Round | GenomeWeb

NEW YORK (GenomeWeb News) – Navigenics has reeled in $18 million in Series C financing from an investment round that included The Procter and Gamble Company, Kleiner Perkins Caufield and Byers, and Mohr Davidow Ventures.

The company plans to use the financing to continue researching ways genomics can be used in preventive health care and to "expand our clinical offerings into exciting new areas and lead the way in making personal genomics an integral part of employer-sponsored preventive health and wellness programs," Navigenics CEO and President Vance Vanier said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.